Published in Immunotherapy Weekly, October 8th, 2003
The rationale is that these preliminary tests would be helpful for further U.S. Food and Drug Administration considerations as well as reinforcement of results that the inventor of Tubercin has established in the past in Korea and elsewhere.
The expectation of HTTD is that scientific results recorded by a third party other than those associated with HTTD will further the company's communication efforts in establishing Tubercin as an immunostimulant for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.